What ‘s hot in India? A US-India VC’s perspective
Vineet Buch of BlueRun has a nice post on “What’s looking promising in India in 2006?” from an investor’s perspective. Some extracts: * Consumer Internet: I predict that the interesting…
Global telecom equipment makers looking at manufacturing in India
Businessworld has a cover story on how and why global telecom equipment firms are beginning to manufacture in India. One of the driving factors behind this growing interest is, without…
Bennett Coleman portfolio crosses 40
The tally of companies in which Bennett, Coleman & Co. (BCCL), the publishers of Times of India and Economic Times, has acquired stakes has crossed 40, according to a Businessworld…
New Seed Funds: Right time, Right Place, Right Model
On Monday (Dec 19), I attended the soft launch of Mentor Partners, a unique technology-focused seed fund, in Bangalore. The firm plans to initially invest $1 million each in 10…
What ails buyouts in India?
Why is it that despite several months of trying, large buyout funds have not been able to close any significant deals in India? The answer seems to be the lack…
Are India’s listed cos. prepared for Clause 49?
Knowledge@Wharton has an article on how India’s public companies must meet a January 1, 2006, deadline to comply with sweeping new corporate governance standards. Extracts: The reforms, ordained by the…
VentureWoods becomes a group blog
VentureWoods a blog started by entrepreneur-turned-VC Alok Mittal has since turned into a platform with multiple contributors (including yours truly) from the Indian VC-Start-up eco-system. Arun Natarajan is the Founder…
TCS steps on the gas
Businessworld has a cover story on TCS’ growth strategies post its IPO. Here is an extract relating to the acquisition strategy of India’ top IT services firm: Apart from HCL…
“Sequoia-Indiatimes deal off”
Sequoia Capital has decided against partnering WestBridge Capital in their proposed investment into Times Internet which operates the Indiatimes.com portal and e-commerce service, reports Businessworld. It was planned that a…
Will Glenmark’s new drug propel it to the big league?
Businessworld profiles Glenmark’s early success with its new experimental drug oglemilast meant to treat asthma and chronic obstructive pulmonary disease. The deal with Forest Labs is worth $190 million (Rs…